AIM: To study the immuno-modulatory effect of resveratrol (RES) on allograft rejection after liver transplantation in rats. METHODS: Male Sprague-Dawley (SD) rats were selected as donors and male Wistar rats as recipients for a rejection model. The recipients were divided into four groups after orthotopic liver transplantation (OLTx). In the RES A, B, and C groups, RES was given intra-peritoneally once a day (25, 50, and 100 mg/kg, respectively) after OLTx, whereas in the control group, vehicle buffer was given intra-peritoneally once a day. The survival time, serum chemistry, production of cytokines, activation of transcription factor NF-kappaB, and histopathologic findings were then compared among these groups. RESULTS: The mean survival time after OLTx in the RES C group was significantly longer than that in the control group (16.7+/-1.2 d vs 9.3+/-0.6 d, P<0.01). On the 7th post-transplant day the serum albumin level significantly improved in the RES C group, the serum total bile acid and alanine aminotransferase (ALT) levels were significantly lower in the RES C group, the serum IL-2 and INF-gamma levels were significantly lower in the RES C group, and the activation of transcription factor NF-kappaB in peripheral blood T lymphocytes was significantly suppressed in the RES A, B, and C groups in comparison to those in the control group. On the 7th post-transplant day, a histological examination revealed apparent difference in the severity of rejection between the RES C group and control group. CONCLUSION: RES has an immuno-suppressive property as well as protective effect on hepatocytes under allograft rejection. It might serve as a novel agent for reducing the severity of hepatic allograft rejection in rats.
AIM: To study the immuno-modulatory effect of resveratrol (RES) on allograft rejection after liver transplantation in rats. METHODS: Male Sprague-Dawley (SD) rats were selected as donors and male Wistar rats as recipients for a rejection model. The recipients were divided into four groups after orthotopic liver transplantation (OLTx). In the RES A, B, and C groups, RES was given intra-peritoneally once a day (25, 50, and 100 mg/kg, respectively) after OLTx, whereas in the control group, vehicle buffer was given intra-peritoneally once a day. The survival time, serum chemistry, production of cytokines, activation of transcription factor NF-kappaB, and histopathologic findings were then compared among these groups. RESULTS: The mean survival time after OLTx in the RES C group was significantly longer than that in the control group (16.7+/-1.2 d vs 9.3+/-0.6 d, P<0.01). On the 7th post-transplant day the serum albumin level significantly improved in the RES C group, the serum total bile acid and alanine aminotransferase (ALT) levels were significantly lower in the RES C group, the serum IL-2 and INF-gamma levels were significantly lower in the RES C group, and the activation of transcription factor NF-kappaB in peripheral blood T lymphocytes was significantly suppressed in the RES A, B, and C groups in comparison to those in the control group. On the 7th post-transplant day, a histological examination revealed apparent difference in the severity of rejection between the RES C group and control group. CONCLUSION: RES has an immuno-suppressive property as well as protective effect on hepatocytes under allograft rejection. It might serve as a novel agent for reducing the severity of hepatic allograft rejection in rats.
Authors: S Kusne; J S Dummer; N Singh; S Iwatsuki; L Makowka; C Esquivel; A G Tzakis; T E Starzl; M Ho Journal: Medicine (Baltimore) Date: 1988-03 Impact factor: 1.889
Authors: Paolo Boscolo; Antonella del Signore; Enrico Sabbioni; Mario Di Gioacchino; Luca Di Giampaolo; Marcella Reale; Pio Conti; Roberto Paganelli; Mario Giaccio Journal: Ann Clin Lab Sci Date: 2003 Impact factor: 1.256
Authors: George R Pettit; Noeleen Melody; Andrew Thornhill; John C Knight; Thomas L Groy; Cherry L Herald Journal: J Nat Prod Date: 2009-09 Impact factor: 4.050
Authors: Luis Bujanda; Elizabeth Hijona; Mikel Larzabal; Marta Beraza; Pablo Aldazabal; Nerea García-Urkia; Cristina Sarasqueta; Angel Cosme; Belen Irastorza; Alberto González; Juan I Arenas Journal: BMC Gastroenterol Date: 2008-09-09 Impact factor: 3.067